NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

肝癌-至2029年的流行病学预测

Hepatocellular Carcinoma - Epidemiology Forecast to 2029

出版商 GlobalData 商品编码 979398
出版日期 内容资讯 英文 62 Pages
订单完成后即时交付
价格
肝癌-至2029年的流行病学预测 Hepatocellular Carcinoma - Epidemiology Forecast to 2029
出版日期: 2020年12月31日内容资讯: 英文 62 Pages
简介

肝细胞癌(HCC)是原发性肝癌的一种常见类型,起源于肝脏中的肝细胞。 HCC的死亡率很高,占所有原发性肝癌的75-90%,使其成为全球第三大癌症死亡率的主要原因(El-Serag和Rudolph,2007; Altekruse,McGlynn和Reichman,2009; Lafaro,Demirjian和Pawlik,2015年;美国癌症治疗中心,2020年)。 肝癌各种分期系统分类,例如巴塞罗那临床肝癌(BCLC)阶段和Child Pugh阶段。 肝癌的主要危险因素是B型肝炎病毒(HBV)感染,C型肝炎病毒(HCV)感染和酗酒(Lafaro,Demirjian和Pawlik,2015)。

本报告提供8大市场(美国、法国、德国、义大利、西班牙、英国、日本、中国)的从2019年到2029年的肝癌发病趋势与危险因素等。

目录

第1章 目录

  • 表格清单
  • 图表清单

第2章 肝癌:摘要整理

  • 促进要素
  • 相关报告
  • 今后的报告

第3章 流行病学

  • 病的背景
  • 危险因素和合并症
  • 世界的趋势及历史的趋势
  • 预测调查手法
    • 来源
    • 预测的前提条件与方法
    • HCC的诊断发病数量
    • 各BCLC阶段HCC的诊断发病数量
    • Child Pugh Stage的HCC诊断发病数量
    • 各危险因素HCC诊断发病数量
    • 各肝硬化对非肝硬化的各HCC诊断发病数量
    • 各生物标记AFPHCC诊断发病数量
    • HCC的5年的诊断盛行率
    • 各BCLC阶段HCC的到目前为止确诊的盛行率
  • HCC的流行病学预测,2019~2029年
    • HCC的诊断发病数量
    • HCC的性别诊断发病数量
    • HCC的各年龄诊断发病数量
    • 各BCLC阶段HCC诊断发病数量
    • Child Pugh 由于Stage的HCC诊断发病数量
    • 各危险因素HCC诊断发病数量
    • 各肝硬化对非肝硬化的各HCC诊断发病数量
    • 各生物标记AFPHCC诊断发病数量
    • HCC的5年的诊断盛行率
    • 各BCLC阶段HCC的到目前为止确诊的盛行率
  • 讨论
    • 流行病学预测的洞察
    • COVID-19的影响
    • 分析的限制
    • 分析的优势

第4章 附录

  • 参考文件
  • 关于作者
    • 流行病学者
    • 检阅者
    • 治疗分析及流行病学的全球董事
    • 医疗保健事业及策略的全球负责人兼EVP
  • 关于GlobalData
  • 咨询方式
  • 免责声明

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GDHCER261-20

Hepatocellular Carcinoma - Epidemiology Forecast to 2029

Hepatocellular carcinoma (HCC) is a common type of primary liver cancer that arises from the hepatocytes in the liver. HCC has a high mortality rate and accounts for 75-90% of all primary liver cancers, making it the third leading cause of cancer mortality worldwide (El-Serag and Rudolph, 2007; Altekruse, McGlynn and Reichman, 2009; Lafaro, Demirjian and Pawlik, 2015; Cancer Treatment Centers of America, 2020). HCC is classified by various staging systems such as the Barcelona Clinic Liver Cancer (BCLC) stage and Child Pugh stages. The major risk factors for HCC are hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, and alcohol abuse (Lafaro, Demirjian and Pawlik, 2015).

Cirrhosis is present in 80-90% of HCC patients and is crucial in the development of HCC. HCC is more common in men than women, averaging between two to four times as many cases in men than in women (El-Serag and Rudolph, 2007; Altekruse, McGlynn and Reichman, 2009). This could be due to men being more likely to be infected with HBV and HCV, consume alcohol, smoke cigarettes, or have increased iron levels (El-Serag and Rudolph, 2007).

In 2019, the 8MM combined had 259,561 diagnosed incident cases of HCC in both sexes for ages 18 years and older. In 2019, Urban China accounted for the majority of these cases, with 154,032 diagnosed incident cases, while the UK accounted for the fewest cases, with 5,700 cases. GlobalData epidemiologists forecast the diagnosed incident cases of HCC to increase to 343,761 cases in 2029 in the 8MM at an Annual Growth Rate (AGR) of 3.24% during the forecast period.

Scope

  • The Hepatocellular Carcinoma (HCC) Epidemiology Report provides an overview of the risk factors and the global and historical trends for HCC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report includes the diagnosed incident cases and five-year diagnosed prevalent cases of HCC in these markets from 2019-2029.
  • The diagnosed incident cases of HCC are further segmented by sex and age (18 years and older), BCLC Stage (stage A, stage B, stage C, and stage D), Child Pugh stage (Child Pugh stage A, Child Pugh stage B, and Child Pugh stage C), HCC risk factors (HBV, HCV, non-alcoholic steatohepatitis [NASH] or non-alcoholic fatty liver disease [NAFLD], and alcohol use), cirrhotic and non-cirrhotic HCC, and biomarkers (Alpha-fetoprotein [AFP], >400ng/mL). Additionally, the report includes the all-time diagnosed prevalent cases of HCC by BCLC stage.
  • The HCC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The HCC Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global HCC market.
  • Quantify patient populations in the global HCC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for HCC therapeutics in each of the markets covered.
  • Understand magnitude of HCC by stage at diagnosis, BCLC stage, Child Pugh stage, risk factors and biomarkers.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Hepatocellular Carcinoma: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
    • 3.4.3 Diagnosed Incident Cases of HCC
    • 3.4.4 Diagnosed Incident Cases of HCC by BCLC Stage
    • 3.4.5 Diagnosed Incident Cases of HCC by Child Pugh Stage
    • 3.4.6 Diagnosed Incident Cases by HCC Risk Factors
    • 3.4.7 Diagnosed Incident Cases of HCC by Cirrhotic Versus Non-cirrhotic HCC
    • 3.4.8 Diagnosed Incident Cases of HCC by Biomarker AFP
    • 3.4.9 Five-Year Diagnosed Prevalent Cases of HCC
    • 3.4.10 All-Time Diagnosed Prevalent Cases of BCLC by Stage
  • 3.5 Epidemiological Forecast for HCC, 2019-2029
    • 3.5.1 Diagnosed Incident Cases of HCC
    • 3.5.2 Sex-Specific Diagnosed Incident Cases of HCC
    • 3.5.3 Age-Specific Diagnosed Incident Cases of HCC
    • 3.5.4 Diagnosed Incident Cases of HCC by BCLC Stage
    • 3.5.5 Diagnosed Incident Cases of HCC by Child Pugh Stage
    • 3.5.6 Diagnosed Incident Cases of HCC by Risk Factors
    • 3.5.7 Diagnosed Incident Cases by Cirrhotic Versus Non-cirrhotic HCC
    • 3.5.8 Diagnosed Incident Cases of HCC by Biomarker AFP
    • 3.5.9 Five-Year Diagnosed Prevalent Cases of HCC
    • 3.5.10 All-Time Diagnosed Prevalent Cases of HCC by BCLC Stage
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 COVID-19 Impact
    • 3.6.3 Limitations of the Analysis
    • 3.6.4 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for HCC

List of Figures

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of HCC (N), Both Sexes, Ages ≥18 Years, 2019 and 2029
  • Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of HCC (N), Both Sexes, Ages ≥18 Years, 2019 and 2029
  • Figure 3: 8MM, Diagnosed Incidence of HC